Introduction {#Sec1}
============

Advances in the treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in the past decade have changed what once was considered a terminal illness into a manageable chronic disease \[[@CR1]\]. Since the introduction of combination antiretroviral therapy (cART) in the mid-1990s, the life expectancy of individuals with HIV has increased dramatically \[[@CR2]--[@CR4]\]. As a result, the estimated number of individuals aged ≥13 years living with AIDS in the United States has more than doubled between 1996 and 2008 (219,318 vs. 479,161, respectively) \[[@CR2]\]. Further, it is estimated that more than 50% of patients with HIV will be over the age of 50 years by 2015 \[[@CR5]\]. Given the longevity achieved with current therapeutic strategies and the increased time patients are on these treatments because of improved efficacy, enhancing the quality of life (QoL) of patients with HIV by reducing symptoms associated with HIV and its treatment has become an important management goal.

Diarrhea remains an important clinical concern and is associated with reduced QoL in individuals with HIV during cART \[[@CR6]--[@CR8]\]. For example, diarrhea contributes to nonadherence or justification for switching from a currently successful cART regimen \[[@CR7], [@CR9]\]. While the rate of opportunistic infections as a cause of diarrhea has decreased in the era of cART, there has simultaneously been a proportionate increase in the incidence of noninfectious diarrhea, often linked to use of antiretroviral therapy \[[@CR7], [@CR10]\]. Protease inhibitors (PI) and other antiretroviral medications may alter the function of the intestinal epithelial barrier and lead to secretory diarrhea, leaky-flux diarrhea, or both \[[@CR11], [@CR12]\]. Detrimental effects of HIV infection itself on the gastrointestinal tract (i.e., HIV enteropathy) constitute another noninfectious cause of diarrhea \[[@CR13]\]. In this review, prevalence, etiology, and current nonpharmacologic and pharmacologic management of noninfectious diarrhea in patients with HIV are described.

Methods {#Sec2}
=======

A search of PubMed was conducted for general information on prevalence, etiology, and treatment options for noninfectious diarrhea in patients with HIV. For treatment updates, PubMed was searched using keywords ("HIV" AND "diarrhea") OR "HIV enteropathy" OR ("antiretroviral" AND "diarrhea") and limited to clinical studies published in English from January 1995 to July 2014. To identify treatment updates on over-the-counter and complementary medicines, the Natural Medicine Comprehensive Database was searched using the keywords "HIV and diarrhea". Bibliographies from included articles were manually reviewed for additional relevant studies. Because of the degree of variance in how diarrhea incidence is reported in clinical trials, the most recent US Food and Drug Administration (FDA)-approved prescribing information was also reviewed for each antiretroviral drug. Additional treatments in development were identified by searching ClinicalTrials.gov.

This article is a review and does not contain any new studies with human or animal subjects performed by any of the authors.

Prevalence of Noninfectious Diarrhea {#Sec3}
------------------------------------

Using observational data to determine prevalence rates is sometimes deemed less valuable than using data from randomized controlled studies. However, evidence exists that with respect to true rates of adverse events (AEs), like noninfectious diarrhea, data from observational studies and randomized controlled trials are comparable \[[@CR14]\]. In order to facilitate reading from either viewpoint, this review has separated observational data from data that have been obtained from controlled clinical studies.

### Observational Studies {#Sec4}

Before the widespread use of cART, up to 70% of patients with HIV reported the development of diarrhea \[[@CR10], [@CR15]\]. From 1995 to 1997 \[[@CR7], [@CR10], [@CR16]--[@CR18]\], as the use of cART increased to \>80% of patients \[[@CR19]\], overall rates of diarrhea decreased but, importantly, the causality changed from infectious to noninfectious \[[@CR10]\]. This is reflected in Table [1](#Tab1){ref-type="table"} \[[@CR7], [@CR10], [@CR16]--[@CR18]\]. The incidence of opportunistic infections causing diarrhea decreased from 53% to 13%, whereas noninfectious causes of diarrhea increased from 32% to 70% \[[@CR10]\]. The predominant cause of noninfectious cases was medication-associated diarrhea, which increased from 0% in 1995 to 45% in 1997. The medications most commonly used by patients during this period were PIs (e.g., nelfinavir, ritonavir, saquinavir, and indinavir) and a nucleoside reverse-transcriptase inhibitor (NRTI; didanosine) \[[@CR10]\].Table 1Incidence of diarrhea in observational studiesStudyStudy description (year)*N*Key resultsCall et al. \[[@CR10]\]Retrospective study of patients with HIV receiving primary care at outpatient HIV clinic (1995--1997)436 in 1995Patients with opportunistic infection etiologies decreased from 53% to 13%; patients with noninfectious diarrhea increased from 32% to 70%^a^582 in 1996739 in 1997Knox et al. \[[@CR16]\]Nutrition for Healthy Living study in inpatient, outpatient settings (1996--1997)67139% of patients reported diarrhea^b^Zingmond et al. \[[@CR17]\]2 cross-sectional cohorts:3,74553% of 3,745 patients reported diarrhea^c^HIV Cost and Service Utilization Study (1996--1997)2,864Veterans Aging Cohort 3 Site Study (1999--2000)881Siddiqui et al. \[[@CR7]\]Prospective study recruiting patients in infectious disease and primary care clinics (2002--2003)41628.2% of patients with HIV vs. 7.1% in HIV-seronegative controls (*p* \< 0.001) reported diarrhea^d^daCosta DiBonaventura et al. \[[@CR18]\]Cross-sectional self-reported survey of patients with HIV receiving cART (2008)95363% of patients reported diarrhea^c^ as cART-related adverse effect*cART* combination antiretroviral therapy, *HIV* human immunodeficiency virus^a^Diarrhea defined as \>3 bowel movements per day for \>2 weeks^b^Diarrhea defined as (1) interfering with normal activity in the past month in a self-reported range of "very little or slightly" to "extremely" (severe diarrhea of ≥6 watery bowel movements per day), or (2) ≥3 loose or watery stools per day in the past month^c^Patient-reported symptom^d^Diarrhea defined as ≥3 bowel movements per day in the past 7 days

Today, despite improvement in gastrointestinal tolerability of the newer agents (including the one most recently approved, dolutegravir) \[[@CR20]\], diarrhea remains a common condition in patients with HIV, including those experiencing virologic and immunologic success \[[@CR7]\]. Two cohort studies found diarrhea rates ranging from 39% \[[@CR16]\] to 60% \[[@CR17]\] and, in one instance, the incidence of diarrhea in a population of people with HIV was quadruple the rate reported for a non-HIV population \[[@CR7]\]. Considering the influence of the class of cART, patients receiving PIs had a higher incidence of diarrhea compared with those on PI-sparing regimens (38% vs. 17%, respectively) \[[@CR7]\]. The impact on patients' lives is best reflected by a 2008 cross-sectional survey of patients with HIV taking cART (*n* = 953), in which diarrhea was ranked second (63.0%) only to fatigue (70.7%) as the most common medication-related AE \[[@CR18]\].

### Randomized Clinical Studies as Cited in Individual cART Component Package Inserts {#Sec5}

The FDA does not standardize or mandate the specific manner in which pharmaceutical manufacturers should report diarrhea within the approved prescribing information (also referred to as package inserts). Table [2](#Tab2){ref-type="table"} outlines the various ways in which these data are presented (by grade, causality, treatment discontinuation, etc.). Package inserts infrequently disseminate incidence rates for all severities of diarrhea. Instead, most only report rates using terms such as "moderate" and "severe" diarrhea, with some including the actual percentages of patients meeting a particular definition (e.g., \>4 loose or watery bowel movements per day). In one example, prescribing information for the non-nucleoside reverse-transcriptase inhibitor (NNRTI) class only reported grade 2 or higher severity of diarrhea using the Division of AIDS grading scale (DIADS) definition \[[@CR21]\], which translated to increase from baseline of 4--6 loose or watery bowel movements per day, poorly reflecting the true incidence of loose stools in persons being prescribed these agents today.Table 2Incidence of diarrhea in patients with HIV for currently marketed antiretroviral therapies based on prescribing information \[[@CR22]\]Drug nameDiarrhea rate, %Diarrhea severity or grade^a^Multiclass combination products Efavirenz, emtricitabine, and tenofovir disoproxil fumarate9Grades 2--4 Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate≥10All grades Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate12All gradesNRTIs Zidovudine\<5All grades Abacavir and lamivudine combination product5^b^Grades 2--4 Abacavir7^c^Grades 2--4 Abacavir, zidovudine, and lamivudine combination product7Grades 2--4 Tenofovir, disoproxil fumarate, and emtricitabine combination product9^b^Grades 2--4 Emtricitabine≥10All grades Tenofovir11^c^Grades 2--4 Lamivudine18All grades Lamivudine and zidovudine combination product18All grades Didanosine19All grades Stavudine50All grades Enteric-coated didanosine57^d^All gradesNNRTIs Etravirine0Grades 2--4 Immediate release; nevirapine\<1--2^e^Moderate to severe Rilpivirine\<2^e^Grades 2--4 Delavirdine2^f^Moderate to severe Efavirenz3^g^Grades 2--4 Extended release; nevirapine4^h^Grade ≥2Protease inhibitors Atazanavir1--3^i^Moderate to severe Indinavir3Moderate to severe Saquinavir8^j^Grades 2--4 Darunavir9 ^h,j^Grade ≥2 Fosamprenavir13^i,j^Moderate to severe Tipranavir15^j^Moderate to severe (Grades 2--4) Ritonavir15--23Moderate to severe Lopinavir and ritonavir combination product15--28^i^Moderate to severe Nelfinavir20^k^Moderate to severeFusion inhibitors Enfuvirtide32^e^All gradesEntry inhibitors Maraviroc≤1^e^All gradesIntegrase inhibitors Dolutegravir≤1^i^Moderate to severe Raltegravir≤1^h^Moderate to severe*AE* adverse event, *NRTI* nucleoside reverse-transcriptase inhibitors, *NNRTI* nonnucleoside reverse-transcriptase inhibitors^a^Grade 1 (mild): temporary episodes of unformed stools or increase from baseline of ≥3 stools during a 24-h period. Grade 2 (moderate): persistent episodes of unformed to watery stools or increase from baseline of 4--6 stools during a 24-h period. Grade 3 (severe): bloody diarrhea or increase from baseline of ≥7 stools during a 24-h period or intravenous fluid supplementation required. Grade 4 (potentially life-threatening): potentially fatal \[[@CR23]\]^b^With efavirenz^c^With lamivudine and efavirenz^d^With nelfinavir and stavudine^e^With background regimen^f^With zidovudine^g^With zidovudine and lamivudine^h^With tenofovir and emtricitabine^i^With NRTI backbone^j^Ritonavir-boosted regimen^k^With stavudine and lamivudine

Up to 28% of patients taking today's commonly used antiretroviral therapies deal with \>4 loose or watery stools per day (see Table [2](#Tab2){ref-type="table"}) \[[@CR22]\]. According to prescribing information, PIs demonstrate the highest average prevalence of diarrhea (13.6%) compared with NRTIs (10.0%, excluding didanosine and stavudine, which are not used commonly in clinical practice today because of greater associated toxicities), while the average rate of diarrhea with NNRTIs is much lower (2.2%). Taken individually, package inserts for the integrase inhibitors (raltegravir and dolutegravir) and the C--C motif receptor 5 (CCR5) antagonists (maraviroc) report some of the lowest incidences of diarrhea (≤1% each class). These figures are in contrast with a comprehensive report using consistent DIADS-based reporting of gastrointestinal AEs \[[@CR21]\], in which up to 19% of patients treated with cART reported grades 2 through 4 diarrhea (i.e., moderate to potentially life-threatening diarrhea) \[[@CR23]\].

#### Protease Inhibitors {#Sec6}

Among the antiretroviral therapy classes, diarrhea is most commonly associated with PIs \[[@CR24]\]. More recently approved agents in this class have a reportedly lower incidence of diarrhea than older agents (Table [2](#Tab2){ref-type="table"}) \[[@CR24]--[@CR27]\]. The primary use of ritonavir is as a pharmacokinetic booster for other PIs (100 mg once daily with atazanavir or darunavir \[in treatment-naïve patients with no documented darunavir-resistant HIV mutations\]; 100 mg twice daily with lopinavir, fosamprenavir, or darunavir \[in treatment-experienced patients with darunavir-resistant HIV mutations\]; or 200 mg twice daily with tipranavir). Partly due to the frequency of gastrointestinal AEs, ritonavir is rarely used today as the sole PI (600 mg twice daily) \[[@CR23]\]. All ritonavir-boosted PIs cause some degree of diarrhea, but data from clinical studies reveal differences in rates of diarrhea according to the PI being used \[[@CR28]\]. Lopinavir/ritonavir (10--11%) and fosamprenavir/ritonavir (13%) cause higher rates of drug-related moderate to severe diarrhea in treatment-naïve patients compared with atazanavir/ritonavir (2%) and darunavir/ritonavir (4%) therapies \[[@CR25]--[@CR27]\].

#### Nucleoside/Nucleotide Reverse-Transcriptase Inhibitors {#Sec7}

It is challenging for clinicians to understand how the NRTIs commonly used today contribute to diarrhea rates in cART-treated patients, as clinical studies with NRTIs report gastrointestinal AEs inconsistently \[[@CR29], [@CR30]\]. In the HIV Study With Epzicom and Truvada (\[EPZ104057; ClinicalTrials.gov identifier NCT00244712\]) study of abacavir/lamivudine versus tenofovir disoproxil fumarate/emtricitabine (*N* = 688), the incidence of grades 2--4 drug-related diarrhea was similar in the tenofovir/emtricitabine and abacavir/lamivudine treatment groups (19% for both arms) in treatment-naïve patients \[[@CR29]\]. However, these patients also received concomitant lopinavir/ritonavir, which is individually reported to generate grade 2 or higher diarrhea in 10--11% of patients \[[@CR25], [@CR26]\]. Clinicians must interpret at the patient level if the additional 8--9% incidence of diarrhea is attributable to the NRTI backbone or other causes. A review of 13 studies evaluating PI-sparing NRTI plus NNRTI cART regimens (included NRTIs were tenofovir/emtricitabine, tenofovir/lamivudine, or zidovudine/lamivudine) in antiretroviral therapy--naïve patients (*N* = 3649) reported that up to 38% (range 0--38%) of patients experienced diarrhea (all definitions of diarrhea were considered) \[[@CR30]\].

#### Non-Nucleoside Reverse-Transcriptase Inhibitors {#Sec8}

Reporting of AEs in clinical trials with NNRTIs (first-generation \[efavirenz and nevirapine\] and second-generation \[etravirine and rilpivirine\]) predominantly limited diarrhea severity data to grades 3 or 4 (or the patient having bloody diarrhea, an increase from baseline of ≥7 stools during a 24-h period, or a need for intravenous fluid supplementation) \[[@CR23]\]. This approach appears to have resulted in gastrointestinal AEs to be reported as rarely occurring. In the AIDS Clinical Trials Group Study A5142 trial (ClinicalTrials.gov identifier: NCT00050895) of treatment-naïve patients, the percentage of patients reporting grade 3 or 4 diarrhea was \<1% in the treatment arm receiving efavirenz plus 2 NRTIs and 3% in the lopinavir/ritonavir plus efavirenz arm \[[@CR31]\]. The apparently lower rate of diarrhea reported for lopinavir/ritonavir may be an artifact of authors reporting only grade 3 or worse diarrhea instead of grade 2 or worse and not reflective of all grades of diarrhea experienced in the population studied. This supports the theory that clinicians are challenged to know the true incidence of clinically meaningful diarrhea in patients due to the lack of standardized reporting and less inclusive FDA labeling requirements.

Notably distinct is the reporting of all grades of diarrhea for etravirine in clinical trials. The rate of all-grade diarrhea in adults was lower for etravirine versus placebo (18% vs. 24%) in a pooled 48-week analysis of the Demonstrate Undetectable viral load in patients Experienced with ARV Therapy studies (DUET-1 \[TMC125-C206\] and DUET-2 \[TMC125-C216\]; ClinicalTrials.gov identifiers NCT00254046 and NCT00255099, respectively) \[[@CR32]\]. The lower incidence versus placebo, although substantial, may help explain why no data on the incidence of diarrhea in adults are reported in the FDA-approved label.

#### Integrase Inhibitors {#Sec9}

In clinical trials, integrase inhibitors (raltegravir, elvitegravir, dolutegravir) demonstrated incidences of moderate to severe diarrhea similar to those observed with placebo. The raltegravir studies (Blocking Integrase in Treatment Experienced Patients with a Novel Compound against HIV BENCHMRCK-1 \[MK-0518\] and BENCHMRCK-2 \[MK-0519\]; ClinicalTrials.gov identifiers NCT00293267 and NCT00293254, respectively) of patients with treatment-resistant HIV infection reported an \~4% incidence of moderate to severe diarrhea in both the raltegravir and placebo groups \[[@CR33]\]. This rate is notably distinct from the incidence of diarrhea of all grades, which was reported in the publication supplement to be 18.4% in the raltegravir group and 21.1% in the placebo group \[[@CR33]\]. From a clinician standpoint, while it is valuable to know the difference in rates between arms of the trial, having a better idea of the true incidence that is likely to occur in patients is also important.

#### Fixed-Dose Combination Antiretroviral Products {#Sec10}

Incidence of diarrhea with fixed-dose combination, single-tablet regimens appears to be based on the side effect profiles of the component medications or, at times, a compilation of data from various studies involving the coformulated agents and the data used in FDA-approved package inserts. For instance, in a 48-week phase 3 clinical trial of efavirenz/emtricitabine/tenofovir disoproxil fumarate, diarrhea of any grade was reported in 8% of patients \[[@CR34]\]. However, in the prescribing information for this formulation, the incidence of moderate to severe diarrhea is reported as 9% (Table [2](#Tab2){ref-type="table"}). The publication on the phase 3, 48-week, clinical trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate reported an incidence of 22% for diarrhea of any grade \[[@CR35]\]. However, the incidence of all grades of diarrhea in the approved labeling is only 12%. This variance in incidence and severity reporting (12% vs. 22%) reinforces the need for individual patients prescribed this combination agent to be assessed by their clinicians for the occurrence of loose stools.

As summarized earlier, clinicians are likely to face challenges when it comes to predicting the true rates of diarrhea occurring in persons taking cART, using only prescribing information. Accordingly, regardless of which combination of antiretroviral therapy is initiated, patients should be counseled to report loose, watery stools or diarrhea to enable their medical providers to determine whether the etiology of the patient's diarrhea is infectious (not covered in this review) or noninfectious.

Etiology of Noninfectious Diarrhea {#Sec11}
----------------------------------

The etiology of noninfectious diarrhea in patients with HIV is multifactorial and most likely includes (in decreasing order of influence) cART-associated diarrhea; the detrimental effects of HIV on the gastrointestinal tract (i.e., HIV enteropathy); and, infrequently, HIV-associated malignancies and pancreatitis \[[@CR36]\].

### cART-Associated Diarrhea {#Sec12}

There are two primary theoretical mechanisms by which cART may cause diarrhea: damage to the intestinal epithelial barrier, which leads to "leaky-flux" diarrhea, and altered secretion of calcium-dependent chloride ions, which causes secretory diarrhea \[[@CR11], [@CR12], [@CR37]\].

Intestinal barrier damage: In in vitro and in vivo studies, PIs induced endoplasmic reticulum stress and activated an unfolded protein response, leading to apoptosis of intestinal cells \[[@CR38]\]. Two caveats to these data are (1) the concentrations of PIs used in these studies substantially exceeded those obtained in humans treated with the FDA-approved doses of PIs \[[@CR6]\], and (2) no substantiation of the leaky-flux model for cART-associated diarrhea in humans has been published.

Altered secretion of chloride ions: Secretory diarrhea is characterized by increased secretion of the chloride ion (Cl^−^) into the lumen, with subsequent sodium and water accompaniment \[[@CR39]\]. Studies specifically evaluating PIs have demonstrated induction of secretory diarrhea via the potentiation of calcium-activated chloride conductance \[[@CR37]\], but published human data supporting this concept are limited. A botanical agent that acts as a dual inhibitor of the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and the calcium-activated chloride channel (CaCC) was shown to improve symptoms of diarrhea and decrease stool chloride concentrations in patients with HIV receiving cART \[[@CR40], [@CR41]\].

### HIV Enteropathy {#Sec13}

HIV enteropathy has been proposed to result from viral infection of gastrointestinal enterocytes, leading to a loss of the intestinal epithelial barrier function of the gastrointestinal mucosa \[[@CR13], [@CR42], [@CR43]\]. This loss may manifest as villous atrophy, crypt hyperplasia, and villous blunting, leading to increased permeability \[[@CR44]\]. Consequent activation of the gastrointestinal immune system, leading to inflammation, may further trigger barrier degradation. Finally, a well-described complication of HIV infection is HIV directly damaging the autonomic nerves of the intestine, leading to faster intestinal transit times \[[@CR6]\].

Implications of Noninfectious Diarrhea in Patients with HIV {#Sec14}
-----------------------------------------------------------

Diarrhea is known to complicate the management of patients with HIV by contributing to nonadherence or causing a need for modification of an otherwise virologically and immunologically successful regimen \[[@CR7], [@CR9]\]. Especially concerning is when patients independently decide to discontinue cART due to diarrhea. In a retrospective study analyzing first-line antiretroviral therapy discontinuation during a 22-year period (1,861 patient-years of follow up), gastrointestinal symptoms were the most common AEs associated with treatment discontinuation \[[@CR9]\]. Adverse event management guidelines recommend careful evaluation of the symptoms and symptomatic management of AEs before switching antiretroviral therapy if AEs are mild to moderate in severity (particularly with diarrhea and nausea) \[[@CR45]\]. As has been illustrated earlier in this review, providers are hampered in their ability to ascertain the true rates of mild to moderate diarrhea for cART agents in use today. This forces healthcare providers to potentially base their decisions on regimen component changes on less than optimal information \[[@CR22]\]. Switching from one antiretroviral therapy to another is a feasible option, although patients who switch therapy are at an increased risk for reduced QoL \[[@CR46]\]. Further, there are a limited number of times for which patients can switch therapies before recycling of antiretroviral agents occur \[[@CR47]\]. Therefore, symptomatic management of mild to moderate AEs before switching from a successful antiretroviral regimen may be preferable.

Management of Noninfectious Diarrhea {#Sec15}
------------------------------------

As a general rule, management of medical conditions begins with lifestyle modification followed by alteration of the offending agent (if considered to be the etiology). When these methods fail, clinicians then resort to available "therapies." Agents selected should result from careful consideration of input from both the patient/caregiver and existing medical literature. Balancing these datasets, healthcare providers develop personal algorithms for management, especially when clear guidance is not available. HIV-associated diarrhea (in patients optimally on stable, successful ART) lacks standardized guidelines. Presented below is a compendium of options with varying degrees of available data and successful outcomes. Where possible, a suggested order of use in patients is provided.

Successful management of diarrhea in patients with HIV has a number of important potential benefits, including improving adherence to cART, enabling patients to maintain an otherwise successful regimen, improving nutritional status, stabilizing weight, and enhancing QoL \[[@CR8], [@CR48], [@CR49]\]. Management of noninfectious diarrhea in patients with HIV receiving cART initially should include supportive nonpharmacologic treatments, followed by pharmacologic treatments, with cART modification as a secondary option. However, limited evidence exists for the use of nonpharmacologic and pharmacologic approaches \[[@CR49]--[@CR55]\]. This review focused on literature involving patients with HIV, as cART requires special considerations.

Nonpharmacologic and Complementary Alternative Medicine Approaches {#Sec16}
------------------------------------------------------------------

Traditional nonpharmacologic agents for the symptomatic treatment of diarrhea in patients with HIV include dietary modifications, use of fiber, and administration or application of other supplements (see Table [3](#Tab3){ref-type="table"}) \[[@CR49], [@CR51]--[@CR55]\].Table 3Nonpharmacologic treatment for noninfectious diarrhea in patients with HIV \[[@CR49], [@CR51]--[@CR55]\]Agent/interventionTheorized mechanism of actionDietary interventionReduces caffeine, fat, and lactose intake, and increases soluble fiber consumptionPsylliumIncreases fiber content and acts as a bulking agentOat branIncreases soluble fiber and acts as a bulking agentProbioticsModulate and normalize enteric floraBovine serum immunoglobulinRestores mucosal immunity and gastrointestinal function by reducing intestinal inflammation[l]{.smallcaps}-GlutamineEnergy source for cells, such as enterocytes; preserves gut mucosal integrityCurcuminAnti-inflammatory agentAcupuncture with moxibustionAffects gastric motility, electrical activity, and secretion of gastric acid, pancreatic enzymes, and bile by stimulating the points along the stomach or spleen channels

### Dietary Modification {#Sec17}

Unfortunately, for the evidence-driven clinician, scientific data supporting the effectiveness of dietary interventions for managing diarrhea in patients with HIV are sparse. A single clinical study of symptom management in HIV-associated diarrhea (*N* = 75) using normal foods (i.e., a low-fat, low insoluble fiber, lactose-free, high soluble fiber, and caffeine-free diet) versus a control group without dietary restrictions reported that after 24 weeks, dietary intervention was effective in reducing stool frequency (*p* = 0.0003) and improving stool consistency (*p* = 0.0002) \[[@CR51]\]. This approach is reasonable and should be encouraged. It is also potentially a beneficial lifestyle modification for patients with HIV, especially those with comorbid conditions of diabetes and obesity.

### Bulking Agents {#Sec18}

Classified by the FDA as food supplements, psyllium and oat bran are bulking agents. Although bulking agents are commonly employed to remedy diarrhea, historically they have shown limited utility in patients with HIV and diarrhea \[[@CR49], [@CR56], [@CR57]\]. Data do not exist regarding use of bulking agents with today's commonly used antiretroviral agents. As an additive or adjunct therapy with dietary modifications, it is relatively inexpensive and there appears little harm to attempting this remedy, if agreeable to the patient.

### Probiotics {#Sec19}

Probiotics, often promoted to "enhance" the immunologic health of the gastrointestinal system \[[@CR58], [@CR59]\], have been studied in the treatment and prevention of diarrhea in patients with HIV. While the mechanism for the effects of probiotics on gastrointestinal immune health have been reported on in more detail elsewhere, the existing evidence for efficacy is conflicting \[[@CR60]\]. In a randomized, crossover, placebo-controlled study in 17 HIV-infected patients with noninfectious diarrhea receiving antiretroviral therapy, the majority of whom (89%) were receiving PIs (nelfinavir or ritonavir), therapy with the probiotic *Lactobacillus rhamnosus* GG for 2 weeks did not significantly affect the frequency or consistency of stools compared with placebo. However, in another randomized, double-blind, clinical study in patients with HIV not receiving antiretroviral therapy, probiotic yogurt containing mixed *Lactobacilli* strains resolved moderate diarrhea in all 12 patients within 2 days of treatment compared with 2 of 12 patients receiving nonprobiotic yogurt (i.e., control group) for 15 days \[[@CR52], [@CR61]\]. In a larger placebo-controlled, randomized study, 69 patients with HIV who were also naïve to antiretroviral therapy received treatment with *Lactobacilli* strains for 25 weeks but reported no significant modification of diarrheal symptoms compared with placebo \[[@CR62]\]. At present, the use of probiotics for the treatment of noninfectious diarrhea in patients with HIV (especially those receiving cART) is not supported in the literature. However, the limited body of evidence does not reflect the wide diversity of probiotics available that have yet to be tested and may demonstrate verifiable efficacy in the future. This approach, similar to bulking agents, falls into the unscientifically grounded category of "unlikely to cause harm" and seems reasonable if favored by the patient.

### Bovine Serum-Derived Immunoglobulin {#Sec20}

This agent is known to reduce inflammation of the intestine, restore mucosal immunity, and improve gastrointestinal function \[[@CR63]\]. In a small, open-label, 8-week study in eight patients with HIV enteropathy, treatment with oral serum-derived bovine immunoglobulin reduced the median number of bowel movements per day (5.8--2.0; *p* = 0.008) and improved stool consistency, as scored on a scale of 1 (formed) to 6 (watery) (5.3--3; *p* = 0.008). A clinical trial of this agent in the treatment of patients with HIV-associated enteropathy is currently ongoing (ClinicalTrials.gov identifier: NCT01828593). This approach, addressing potentially two of the theoretical causes of HIV enteropathy, is scientifically sound. It shows promise, but definitive data are pending. Bovine serum-derived immunoglobulin is currently available as a medical food and is FDA approved for use in clinical dietary management of enteropathy, including HIV-associated forms \[[@CR64]\]. Its place within the treatment decision algorithm should be known following completion of ongoing clinical trials.

### [l]{.smallcaps}-Glutamine {#Sec21}

In a randomized, placebo-controlled study of 25 patients with HIV and nelfinavir-induced diarrhea, supplementation with [l]{.smallcaps}-glutamine significantly reduced the severity of diarrhea. Based on a 5-point scale for assessment of bowel movements, with normal = grade 0 and \>7 stools/day = grade 4, the mean grade of diarrhea for patients taking [l]{.smallcaps}-glutamine was 0.76, compared with a mean grade of diarrhea of 1.85 for patients who received placebo; *p* \< 0.01 \[[@CR53], [@CR65]\]. However, this approach has not been replicated by others, nor has it been evaluated using cART agents commonly prescribed today. Further data would be beneficial to interpret where [l]{.smallcaps}-glutamine fits into the treatment paradigm.

### Curcumin {#Sec22}

The beneficial effects of curcumin have been reported in the treatment of various disease states. The mechanism of action of curcumin in diarrhea is theorized to be related to its anti-inflammatory properties (the reader is referred to Dulbecco and Savarino 2013 \[[@CR66]\] for a comprehensive review of this agent and its potential medicinal properties). Curcumin is a naturally occurring hydrophobic phenol extracted from turmeric, which is best known as the primary spice in curry or the yellowing agent for some varieties of mustard. With respect to HIV-associated diarrhea, there is a single clinical study (*n* = 8) of patients treated with curcumin for a mean of 41 weeks (7/8 patients were receiving cART) \[[@CR54]\]. In this case series of eight patients, curcumin therapy resulted in rapid (mean 13 days) and complete resolution of diarrhea and normalization of stool quality. No additional studies replicating these results with curcumin have been published. More standardized studies of the efficacy of curcumin as a therapeutic agent for diarrhea are needed before curcumin treatment can be recommended. Clinicians who wish to consider adding it to patients' diet as a dietary supplement are encouraged to first formally evaluate the balance necessary between other dietary elements and curcumin concentration to maintain the antidiarrheal effect of curcumin.

### Acupuncture {#Sec23}

The combination of acupuncture and moxibustion (application of heat generated by burning of an herbal mixture containing *Artemisia*) has been used to address the bowel patterns of patients with HIV; however, evidence for the effectiveness of this therapy is limited \[[@CR55]\]. While many patients with HIV may receive acupuncture to alleviate symptoms, it would likely take a clinical research network-generated, peer-reviewed publication describing the antidiarrheal effect of acupuncture and moxibustion to fully inform practicing clinicians and patients alike on this particular use. Until sufficient data are available, this treatment modality cannot be recommended.

Pharmacologic Options {#Sec24}
---------------------

### Adsorbents {#Sec25}

Adsorbents such as bismuth subsalicylate and attapulgite act by adsorbing fluids and compounds to improve stool consistency (see Table [4](#Tab4){ref-type="table"}) \[[@CR67]\]. This approach for managing HIV-associated noninfectious diarrhea has been considered based on the high degree of success observed in some patients using adsorbents to treat travelers' diarrhea \[[@CR68], [@CR69]\]. However, the etiology and pathophysiology of travelers' diarrhea is distinct from that of HIV-associated noninfectious diarrhea, and the success of therapies for travelers' diarrhea has not transferred to the setting of HIV \[[@CR70]\]. Clinical evidence for the use of these agents in controlling diarrhea in the HIV population is limited to one randomized, double-blind study that reported that attapulgite was no better than placebo for improving stool consistency or stool frequency in adults with HIV and diarrhea \[[@CR67], [@CR71]\]. These agents cannot be recommended for use at this time for the treatment of HIV-associated noninfectious diarrhea.Table 4Pharmacologic treatment for noninfectious diarrhea in patients with HIV \[[@CR50], [@CR67], [@CR73]\]DrugMechanism of actionAdverse effects/drug--drug interactions and additional informationAdsorbents (attapulgite and bismuth subsalicylate)AdsorbentCan cause constipation; no evidence of drug--drug interactions with components of cARTLoperamideAntimotility agentCramping, constipation; potential drug interaction with numerous antiretroviral therapies; familiar to patientsDiphenoxylate/atropineAntimotility agentAbuse potentialOctreotideAntisecretory agentPotentially serious hormonal and gastrointestinal disturbances; injectableCrofelemerAntisecretory agentLow rate of AEs; no clinically relevant drug--drug interactions*AE* adverse event, *cART* combination antiretroviral therapy

### Antimotility Agents {#Sec26}

Oral antimotility agents such as loperamide and diphenoxylate/atropine are opioid derivatives, which increase fecal transit time by decreasing bowel activity and increasing tone in the large intestine. These actions, in turn, provide greater opportunity for the potentially leaky gastrointestinal tract to absorb fluid from the gut \[[@CR67]\].

#### Loperamide {#Sec27}

The best evidence for chronic use of loperamide in patients with HIV comes from a study that included concomitant use of antimicrobial treatment for intestinal infections, which does not allow for conclusions to be drawn on loperamide efficacy in the management of noninfectious diarrhea \[[@CR72]\]. A retrospective study, published in abstract form in 1998 and cited in reviews, indicated that 32% of patients with HIV receiving nelfinavir responded to loperamide treatment for the management of diarrhea \[[@CR49]\]. However, the use of loperamide, particularly for long-term management, may be limited by treatment-related AEs, including drug interactions with antiretroviral therapy \[[@CR73], [@CR74]\]. As a P-glycoprotein (P-gp) substrate unable to cross the blood--brain barrier (P-gp efflux pump prevents this translocation), loperamide generally only possesses peripheral opioid activity \[[@CR75]\]. Although PIs (as P-gp inhibitors) could increase loperamide levels in the brain, potentially causing respiratory depression \[[@CR76]\], formal evaluation of coadministration of loperamide with ritonavir-boosted tipranavir did not result in any clinically relevant central nervous system opioid effects \[[@CR75]\]. Given the substantial clinical history of use of loperamide to treat diarrhea in patients with HIV, despite minimal supporting peer-reviewed evidence, loperamide represents a relatively safe and inexpensive first-line approach.

#### Diphenoxylate/Atropine {#Sec28}

Data on the use of diphenoxylate/atropine for the treatment of diarrhea in patients with HIV are sparse. There are anecdotal, non-peer-reviewed reports of low-dose (1--5 mg) diphenoxylate/atropine for the treatment of PI-induced diarrhea. However, in one published trial of six patients previously unresponsive to loperamide therapy, there was no benefit with diphenoxylate/atropine \[[@CR49]\]. In addition, as diphenoxylate crosses the blood--brain barrier at high doses, this potentially leads to dependence and abuse, further discouraging use of this product \[[@CR73]\]. As with loperamide, the evidence for use of diphenoxylate/atropine to treat diarrhea in patients with HIV is primarily anecdotal. Despite its long-standing history of availability, this agent should be reserved for patients unresponsive to other options, given its propensity for AEs (including constipation and abuse risk).

### Antisecretory Agents {#Sec29}

Octreotide and crofelemer are antisecretory agents with peer-reviewed published data showing their efficacy in treating diarrhea in patients with HIV. These agents inhibit secretory processes within the enterocyte, but the mechanism for their effects, safety profiles, and drug--drug and drug--disease interaction potentials vary greatly.

#### Octreotide {#Sec30}

This semisynthetic analogue of somatostatin (a key regulatory protein of the lower gastrointestinal tract that causes slower gastrointestinal transit times) is administered for the symptoms of metastatic carcinoid tumors and vasoactive intestinal peptide secreting adenomas (both resulting in loose, watery diarrhea) \[[@CR77]\]. The non-depot formulation of subcutaneously injected octreotide has been administered for symptomatic treatment of diarrhea in patients with HIV; results of published studies have been mostly positive but not limited to noninfectious diarrhea populations \[[@CR73], [@CR78]--[@CR82]\]. Cello et al. \[[@CR78]\] evaluated 51 males and females with or without concomitant *Mycobacterium*, *Cryptosporidium* or microsporidial infections and refractory diarrhea. Reductions in stool volumes of 50% or greater over 21 days were reported when patients were treated every 8 h with incrementally increasing doses of octreotide \[[@CR78]\]. In 1996, Beaugerie et al. \[[@CR79]\] reported a profound response from a mean ± SE stool frequency at baseline of 5.7 ± 1.8 to 1.3 ± 0.9 after 1 week of up to thrice daily dosing of octreotide in 3 (23%) of the study participants. It must be emphasized, however, that octreotide can cause serious, severe hormonal effects (altered balance between insulin, glucagon, and growth hormone, resulting in hypoglycemia and hyperglycemia), along with gastrointestinal disturbances such as gallbladder contractility (resulting in biliary tract abnormalities including sludge); nausea; abdominal discomfort; constipation; and, paradoxically, diarrhea \[[@CR77]\]. Equally important is the impact that octreotide, a subcutaneously administered agent, may have on the absorption of orally administered agents, including antiretrovirals. Overall, octreotide is rarely administered in clinical practice for the management of diarrhea in patients with HIV and should only be considered after careful evaluation of risk--benefit.

#### Crofelemer (SP-303) {#Sec31}

Crofelemer is an FDA-approved, orally administered, minimally absorbed, botanical drug derived from the stem bark latex of the *Croton lechleri* tree \[[@CR83]\]. Crofelemer is an inhibitor of both the cAMP-stimulated CFTR chloride channel and the CaCC; both of these ion channels regulate Cl^−^ and fluid secretion via intestinal epithelial cells \[[@CR84]\] and are proposed as mechanisms of antidiarrheal action for this agent.

Pharmacokinetic data indicate minimal systemic absorption of oral crofelemer, irrespective of concomitant food intake or duration of exposure \[[@CR41], [@CR83], [@CR85]\]. Data from in vitro studies have shown that there is no cytochrome P450-mediated metabolism at clinical concentrations of crofelemer, and no clinically relevant drug--drug interactions with nelfinavir, zidovudine, and lamivudine \[[@CR85]\]. Although these antiretroviral agents are poor representatives of antiretrovirals commonly used today, the available published literature reflects currently used agents (as described later) without loss of clinical efficacy noted.

The two clinical studies published to date on the use of crofelemer in HIV-associated, non-infectious diarrhea have largely shown positive results using various outcome measures (including somewhat inconsistent and subjective approaches) such as stool weight and volume, patient reported improvement, etc. \[[@CR40], [@CR41]\].

In the initial phase 2 (randomized, double-blind, placebo-controlled) study in patients with HIV-associated diarrhea (*N* = 51; 41/51 patients on cART and 39/41 patients on PI), crofelemer treatment (500 mg every 6 h for 4 days) resulted in a reduction in mean stool weight compared with placebo on day 4 (451.3 vs 150.7 g/day; *p* = 0.14) but only numerically reduced the stool frequency compared with placebo in the same time frame (3.0 vs 2.0 stools/day; *p* = 0.3) \[[@CR40]\].

The second study (*N* = 374) demonstrated that significantly more patients receiving crofelemer 125 mg twice daily obtained a reduction from an average of 2.7 watery stools per day (\~17 watery stools per week) to \<2 watery stools per week for ≥2 of the 4-week double-blinded, randomized treatment periods compared with placebo (17.6% vs. 8.0%, *p* = 0.01) \[[@CR41]\]. Other outcome measures favoring crofelemer 125 mg twice daily over placebo were daily watery bowel movements (−0.96 vs. −0.75; *p* = 0.04) and daily stool consistency score (−0.43 vs. −0.28; *p* = 0.02). A key determinant of success appears to be patients previously failing to respond to antidiarrheal therapy (18.1% vs. 3.5%, *p* = 0.002). Duration of use in the double-blind phase and the 20-week placebo-free extension phase appeared to be consistent with response and supports the phase 2 findings of trends toward improvement with exposure \[[@CR40], [@CR41]\].

The safety profile for crofelemer was comparable to that of placebo in each dose group. Changes from baseline in HIV clinical parameters (i.e., HIV viral load and CD4+ cell counts) and antiretroviral adherence were minimal, nondetrimental, and comparable between crofelemer and placebo treatment groups during the placebo-controlled phase. The results from these studies suggest that crofelemer should be considered for patients who have failed with over-the-counter loperamide or other antidiarrheal drugs. Importantly, if used, patients must be informed that the benefit is not immediate and improves with continued use. Because crofelemer was not formally studied in combination with loperamide, clinicians should use their judgement to bridge crofelemer onset of effect (anecdotally perceived to be \~4 weeks by the primary author) with intermittent loperamide use. This hypothesis warrants formal investigation. Also, it is worthwhile noting that if no benefit is seen within 3 months, crofelemer should be discontinued and alternatives considered.

Conclusions {#Sec32}
===========

Diarrhea in patients with HIV is a significant unmet clinical need that contributes to worsening QoL and complicates the medical management of HIV infection. Because diarrhea incidence is inconsistently reported in clinical trials and package inserts of antiretroviral agents, and because the definitions used to generate rates of diarrhea for patients with HIV receiving cART tend to vary, clinicians are strongly encouraged to question all patients on any cART about their personal experiences with loose, watery stools. Complicating patient management further, the availability of published, peer-reviewed evaluations of treatments for noninfectious diarrhea in patients with HIV is limited. Weighing the entirety of the available information, it appears that if diet modifications, including introduction of psyllium and fiber, fail to resolve a case of confirmed noninfectious diarrhea in patients with HIV, loperamide followed by crofelemer should be considered. Beyond this recommendation, the clinician is encouraged to review the most recent literature available, not relying upon prescribing information. The key to success at each stage of management is for medical professionals to ensure that their patients' incidences of watery stools have been resolved within 1 month of the start of treatment so as to avoid continuation of ineffective therapies and decrease the likelihood of antiretroviral discontinuation.
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